{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:29:35Z","timestamp":1786969775313,"version":"build-2736575974"},"reference-count":15,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>CHAPLE syndrome is an ultra-rare genetic cause of protein-losing enteropathy (PLE) resulting from uncontrolled complement activation due to CD55 deficiency. We report two paediatric patients presenting with recurrent diarrhoea, hypoalbuminaemia, hypogammaglobulinaemia and growth failure, both initially evaluated as intestinal lymphangiectasia. Persistent symptoms and poor response to conventional therapy prompted genetic evaluation, which revealed pathogenic variants in the CD55 gene in both children, confirming the diagnosis of CHAPLE syndrome. Both patients required repeated albumin and intravenous immunoglobulin replacement prior to diagnosis. Targeted therapy with pozelimab was initiated. Rapid clinical and biochemical improvement was observed within 2\u2009weeks, with sustained normalisation of albumin, total protein and immunoglobulin levels. At 3-month follow-up, both children remained in clinical remission without further need for albumin or immunoglobulin infusions. These cases highlight the importance of considering genetic causes in children with refractory PLE and demonstrate the effectiveness of early targeted complement inhibition in CHAPLE syndrome.<\/jats:p>","DOI":"10.1136\/bcr-2026-273991","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:20:11Z","timestamp":1786969211000},"page":"e273991","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted complement inhibition with pozelimab in children with CD55 deficiency"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-697X","authenticated-orcid":false,"given":"Rohan","family":"Grotra","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, All India Institute of Medical Sciences New Delhi, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Bhadani","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, All India Institute of Medical Sciences New Delhi, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Malik","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, All India Institute of Medical Sciences New Delhi, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026081705200737000_19.8.e273991.1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0016-5085(19)35130-3","article-title":"The role of the gastrointestinal system in \u201cidiopathic hypoproteinemia\u201d","volume":"41","author":"WALDMANN","year":"1961","journal-title":"Gastroenterology"},{"key":"2026081705200737000_19.8.e273991.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615887"},{"key":"2026081705200737000_19.8.e273991.3","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-024-03277-9","article-title":"Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments","volume":"19","author":"Litcher-Kelly","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"2026081705200737000_19.8.e273991.4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MPG.0000000000002198","article-title":"Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency","volume":"68","author":"Kurolap","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026081705200737000_19.8.e273991.5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40265-023-01955-9","article-title":"Pozelimab: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"2026081705200737000_19.8.e273991.6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(23)02358-9","article-title":"Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study","volume":"403","author":"Ozen","year":"2024","journal-title":"Lancet"},{"key":"2026081705200737000_19.8.e273991.7","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8327-1"},{"key":"2026081705200737000_19.8.e273991.8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41590-020-00830-z","article-title":"Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease","volume":"22","author":"Ozen","year":"2021","journal-title":"Nat Immunol"},{"key":"2026081705200737000_19.8.e273991.9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaci.2025.04.020","article-title":"Complement dysregulation at lymphatics","volume":"156","author":"Ozen","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026081705200737000_19.8.e273991.10","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2492774"},{"key":"2026081705200737000_19.8.e273991.11","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/14656566.2024.2388267","article-title":"Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?","volume":"25","author":"Can","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026081705200737000_19.8.e273991.12","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3748\/wjg.v24.i28.3198","article-title":"Genetic analysis is helpful for the diagnosis of small bowel ulceration","volume":"24","author":"Umeno","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026081705200737000_19.8.e273991.13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/ibd\/izac001","article-title":"Novel CD55 Mutation Associated With Severe Small Bowel Ulceration Mimicking Inflammatory Bowel Disease in a Pair of Siblings","volume":"28","author":"Chongsrisawat","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026081705200737000_19.8.e273991.14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMc1707173","article-title":"Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy","volume":"377","author":"Kurolap","year":"2017","journal-title":"N Engl J Med"},{"key":"2026081705200737000_19.8.e273991.15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/1750743X.2026.2639273","article-title":"Evaluating pozelimab in the treatment of CHAPLE disease","volume":"18","author":"Ozturk","year":"2026","journal-title":"Immunotherapy"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-273991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:20:13Z","timestamp":1786969213000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-273991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,17]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bcr-2026-273991"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-273991","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}